Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2

Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2

Until today effective antivirals for COVID-19 treatment are not widely available. Here, Zhao et al. characterize a dual-functional cross-linking peptide, 8P9R, that can inhibit SARS-CoV-2 virus entry in vitro and suppresses viral replication in vivo in golden Syrian hamster.

Guardado en:
Detalles Bibliográficos
Autores principales: Hanjun Zhao, Kelvin K. W. To, Hoiyan Lam, Xinxin Zhou, Jasper Fuk-Woo Chan, Zheng Peng, Andrew C. Y. Lee, Jianpiao Cai, Wan-Mui Chan, Jonathan Daniel Ip, Chris Chung-Sing Chan, Man Lung Yeung, Anna Jinxia Zhang, Allen Wing Ho Chu, Shibo Jiang, Kwok-Yung Yuen
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/7afe365d9513460da362a27eacf0cb49
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Until today effective antivirals for COVID-19 treatment are not widely available. Here, Zhao et al. characterize a dual-functional cross-linking peptide, 8P9R, that can inhibit SARS-CoV-2 virus entry in vitro and suppresses viral replication in vivo in golden Syrian hamster.

Ejemplares similares